Skip to main content
SION
NASDAQ Life Sciences

Sionna Posts $32.4M Q3 Loss; $249.8M Cash Funds Operations Into 2H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.52
Mkt Cap
$161.408M
52W Low
$3.19
52W High
$54.97
52W Position info
10% above low
Off High info
94% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SION is trading near its 52-week low of $3.19 (10% above the low).

Summary

Sionna reported a $32.4M Q3 2026 net loss and $249.8M in cash, extending its runway into the second half of 2029, and said it will start the AscenSION CF Phase 2 trial of SION-451 + SION-2222 in Q1 2027.


Key Events · Earnings and Guidance · SION

  • Q3 Loss Widens to $32.4M

    Net loss was $32.4M, or $0.72 per share, versus $20.3M a year earlier, driven by R&D of $22.0M and G&A of $12.8M including restructuring costs from the September workforce cut.

  • Cash Runway Extended to 2H 2029

    Cash, cash equivalents and marketable securities totaled $249.8M at September 30, 2026, which management expects to fund operations into the second half of 2029.

  • AscenSION CF Phase 2 Set for Q1 2027

    The open-label proof-of-concept trial of SION-451 + SION-2222 in F508del-homozygous patients will start in the first quarter of 2027, assessing sweat chloride, safety and PK over 28 days after switching from Trikafta.

  • Post Hoc Data Support NBD1 Activity

    Excluding three participants with exposures consistent with dosing non-adherence, PreciSION CF showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta.


Analysis · SION · Life Sciences

Investors now have the first hard numbers since Sionna cut 46% of its staff in September and narrowed its focus to the SION-451 + SION-2222 dual combination. The loss widened to $32.4M from $20.3M a year ago on higher R&D and restructuring costs, but $249.8M of cash now stretches the runway into the second half of 2029 — roughly two and a half years beyond the prior 2028 guide. That removes any near-term financing pressure and turns the unused $250M ATM into a backstop rather than a necessity. The key forward item is the AscenSION CF Phase 2 proof-of-concept trial, now slated to start in Q1 2027; that readout is what the story hinges on, and the delay-free timeline plus extended cash means the company can fund it without selling stock at $3.52.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SION was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.4M. The 52-week trading range was $3.19 to $54.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SION - Latest Insights

SION
Sep 17, 2026, 5:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $7.41
Real-time Price: $3.52 info
Change: -$3.89 (-52%) info
Market Cap: $161.408M info
SION
Sep 14, 2026, 4:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $7.93
Real-time Price: $3.52 info
Change: -$4.41 (-56%) info
Market Cap: $161.408M info
SION
Sep 14, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.20
Real-time Price: $3.52 info
Change: -$4.68 (-57%) info
Market Cap: $161.408M info
SION
Aug 10, 2026, 9:07 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $5.34
Real-time Price: $3.52 info
Change: -$1.82 (-34%) info
Market Cap: $161.408M info
SION
Aug 10, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.25
Real-time Price: $3.52 info
Change: -$0.730 (-17%) info
Market Cap: $161.408M info